Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 5/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.40 |
| ▸ | EP300 | Q09472 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15344201 | 0.80 | PDK2 (0.42) | PFKFB3PDK2EP300BRD4CREBBP | |
| SCHEMBL14870415 | 0.80 | PFKFB3 (0.57) | RXRARXRBRXRGPFKFB3 | |
| SCHEMBL21876291 | 0.78 | MAP4K4 (0.46) | PDK2EP300BRD4CREBBP | |
| SCHEMBL15340950 | 0.78 | PIK3CD (0.47) | RXRARXRBRXRGPFKFB3PDK2 | |
| SCHEMBL29373029 | 0.78 | MAP4K4 (0.46) | PDK2EP300BRD4CREBBP | |
| SCHEMBL18086771 | 0.77 | PDK2 (0.47) | PDK2EP300BRD4CREBBPKDM5B | |
| SCHEMBL15341909 | 0.77 | PIM1 (0.47) | PDK2KDM5BMAP3K5 | |
| SCHEMBL16259634 | 0.77 | PDK2 (0.38) | PDK2EP300BRD4CREBBPKDM5B | |
| SCHEMBL15340952 | 0.75 | PRMT5 (0.49) | RXRARXRBRXRGPFKFB3PDK2 | |
| SCHEMBL5352034 | 0.74 | RXRA (0.62) | RXRARXRBRXRGPTPN5BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9096586-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | RXRA 1408/4885RXRB 1416/4885RXRG 1133/4885 |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | RXRA 1414/4885RXRB 1016/4885RXRG 1022/4885 |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | RXRA 396/4885RXRB 581/4885RXRG 365/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | RXRA 1408/4885RXRB 1416/4885RXRG 1133/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | RXRA 1408/4885RXRB 1416/4885RXRG 1133/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | RXRA 396/4885RXRB 581/4885RXRG 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.